NCT04488601View on ClinicalTrials.gov

Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study

PHASE2CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

December 30, 2023

Study Completion Date

December 30, 2023

Conditions
Aging
Interventions
DRUG

Rapamycin

Rapamycin in 2 different dosage forms.

DRUG

Placebo

Placebo capsules

Trial Locations (1)

60605

AgelessRx, Chicago

Sponsors

Lead Sponsor

AgelessRx
All Listed Sponsors
collaborator

University of California, Los Angeles

OTHER

lead

AgelessRx

INDUSTRY

NCT04488601 - Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study | Biotech Hunter | Biotech Hunter